Article Text

Download PDFPDF
Clostridioides difficile-induced diarrhoea following dasatinib therapy
  1. Amlan Kusum Datta1,
  2. Partha Debnath2,
  3. Uddalak Chakraborty3 and
  4. Atanu Chandra3
  1. 1Neurology, Institute of Postgraduate Medical Education and Research Bangur Institute of Neurology, Kolkata, India
  2. 2Gastroenterology, Topiwala National Medical College, Mumbai, India
  3. 3Internal Medicine, RG Kar Medical College and Hospital, Kolkata, India
  1. Correspondence to Dr Atanu Chandra; chandraatanu123{at}


Dasatinib, an oral tyrosine kinase inhibitor, is approved for therapy of chronic myeloid leukaemia (CML). Common adverse effects of this therapy include myelosuppression, fluid retention and diarrhoea. However, Clostridioides difficile infections (CDIs) in the context of dasatinib therapy, without a history of antecedent antibiotic use, has not been reported previously. We present here a case of a 36-year-old man diagnosed with accelerated phase of CML, who was started on treatment with dasatinib. Two months into therapy, he experienced profuse diarrhoea and abdominal pain. Colonoscopy revealed multiple confluent colonic mucosal ulcerations. Immunoassay study of stool revealed positive C. difficile toxin. The patient was started on oral metronidazole, with discontinuation of all other drugs, including dasatinib. He made a complete uneventful recovery following 2 weeks of antibiotic therapy. Chemotherapeutic agents, such as dasatinib, should be considered as possible etiological agents in the pathogenesis of CDI, even in absence of antibiotic use.

  • Chronic Myeloid Leukemia
  • Dasatinib
  • Infection (gastroenterology)
  • Unwanted effects / adverse reactions

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors AKD contributed to conception, initial drafting of manuscript, critical revision of content and final approval of the manuscript. PD, UC and AC contributed to patient management, conception, critical revision of content and final approval of manuscript. All authors are in agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer-reviewed.